Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia
Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia
复制标题
DOI：
10.1182/blood.v94.11.3717.423k09_3717_3721
复制
发表时间：
1999-12-01
期刊：
影响因子：
20.3
通讯作者：
Albitar, M
中科院分区：
文献类型：
--
作者：
Aguayo, A;Estey, E;Albitar, M
血管内皮生长因子（VEGF）是一种有效的血管内皮细胞丝裂原。它与实体瘤的血管生成、生长、播散、转移和预后不良有关。探讨新诊断急性髓性白血病（AML）的细胞VEGF水平及其预后意义。我们使用放射免疫测定法（RIA）来量化从1996年至1998年在MD安德森癌症中心治疗的99例新诊断的AML患者治疗前获得的储存样本中的VEGF水平。这99名患者的结果代表了这些年来在该机构观察到的所有诊断为这种疾病的患者，但这99名患者的白细胞（WBC）和原细胞计数高于其他患者。Western blot证实了RIA的结果。VEGF水平升高与生存期缩短相关（P = 0.01）。以及从治疗开始和完全缓解（CR）日期起更短的无病生存期。相比之下，VEGF水平与WBC或细胞计数之间没有关系，VEGF水平与年龄、细胞遗传学、运动状态或既往血液系统疾病等既定预后因素之间也没有关系，多因素分析表明，在考虑了这些因素和治疗后，VEGF仍然是上述结果的预后因素。我们的研究结果表明，至少在白细胞计数和细胞计数较高的AML患者中，细胞VEGF水平是预后的独立预测因子。(C) 1999年由美国血液病学会出版。
Vascular endothelial growth factor (VEGF) is a potent mitogen for vascular endothelial cells. It has been associated with angiogenesis, growth, dissemination, metastasis, and poor outcome in solid tumors. To assess cellular VEGF levels and their prognostic significance in newly diagnosed acute myeloid leukemia (AML). we used a radioimmunoassay (RIA) to quantify VEGF levels in stored samples obtained before treatment from 99 patients with newly diagnosed AML treated at the MD Anderson Cancer Center from 1996 to 1998. Outcome in the 99 patients was representative of that observed in all patients seen at this institution with this diagnosis during these years, but the 99 patients had higher white blood cell (WBC) and blast counts than the other patients. Results of the RIA were confirmed by Western blot. There was a relationship between increasing VEGF levels and shorter survival (P = .01). as well as shorter disease-free survival, both from start of treatment and from complete response (CR) date. In contrast, there was no relationship between VEGF level and WBC or blast count, or between VEGF lever and such established prognostic factors as age, cytogenetics, performance status, or presence of an antecedent hematologic disorder, and multivariate analysis indicated that VEGF was still prognostic for the above outcomes after accounting for these factors, as well as treatment. Our results suggest that at least in AML patients with higher WBC and blast counts, cellular VEGF level is an independent predictor of outcome. (C) 1999 by The American Society of Hematology.